Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;13(11):100840.
doi: 10.1016/j.tranon.2020.100840. Epub 2020 Aug 18.

Drug screening model meets cancer organoid technology

Chen Liu  1 , Tianyu Qin  1 , Yuhan Huang  1 , Yuan Li  1 , Gang Chen  1 , Chaoyang Sun  2
Affiliations
Review

Drug screening model meets cancer organoid technology

Chen Liu et al. Transl Oncol. 2020 Nov.

Abstract

Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived xenograft (PDX). So, cancer organoid has been widely applied to preclinical drug evaluation, biomarker identification, biological research, and individualized therapy. Besides, cancer organoid can be preserved, resuscitated, passed infinitely, and mechanically cultured on a chip for drug screening; it has become one of the partial models for low/high-throughput drug screening in the preclinical trial in vitro. Therefore, this review presents the recent developments of tumor organoids for drug screening, which will introduce from four aspects, including the stability/credibility, types, application, deficiency and prospect of the tumor organoids model for drug screening.

Keywords: Cancer organoid; Drug screening; Precision therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Unlabelled Image
Graphical abstract
Fig. 1
Fig. 1
Cancer models for drug screening in vitro.
See this image and copyright information in PMC

References

    1. Harrison R.K. Phase II and phase III failures: 2013-2015. Nat. Rev. Drug Discov. 2016;15:817–818. - PubMed
    1. Tuveson D., Clevers H. Cancer modeling meets human organoid technology. Science. 2019;364:952–955. - PubMed
    1. Kalamara A., Tobalina L., Saez-Rodriguez J. How to find the right drug for each patient? Advances and challenges in pharmacogenomics. Curr Opin Syst Biol. 2018;10:53–62. - PMC - PubMed
    1. Srivastava P., Kumar M., Nayak P. 2016. Role of Patient Derived Cell Lines and Xenograft in Cancer Research. The Pharmstudent; p. 27.
    1. Scherer W.F., Syverton J.T., Gey G.O. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med. 1953;97:695–710. - PMC - PubMed